New drug duo targets Hard-to-Treat blood cancers
NCT ID NCT04702425
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tested two experimental drugs, VOB560 and MIK665, given together to people with certain blood cancers (non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma) that had come back or stopped responding to treatment. The main goals were to find safe doses and see if the combination could shrink tumors. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
HUS, FIN-00029, Finland
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Sunto Gun, Shizuoka, 411 8777, Japan
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.